000			04138nam a22003495i 4500
001			234529
003			ES-VaUE
005			20221220020608.0
007			cr nn 008mamaa
008			100301s2007 xxu| s |||| 0|eng d
020			_a9781597451659
024	7		_a10.1385/1597451657 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC
245	1	0	_aTarget Discovery and Validation Reviews and Protocols _bEmerging Strategies for Targets and Biomarker Discovery, Volume 1 _cedited by Mouldy Sioud.
250			_a1st edition 2007
264		1	_aTotowa, NJ _bHumana Press _c2007
300			_a1 recurso en línea (XII, 354 páginas) _b89 ilustraciones, 3 ilustraciones a color
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
490	0		_aMethods in Molecular Biology _x1940-6029 _v360
505	0		_aMain Approaches to Target Discovery and Validation -- Bioinformatics Approaches to Cancer Gene Discovery -- Analysis of Gene Networks for Drug Target Discovery and Validation -- Target Discovery and Validation in Pancreatic Cancer -- Molecular Classification of Breast Tumors -- Discovery of Differentially Expressed Genes -- Genome-Wide Screening by Using Small-Interfering RNA-Expression Libraries -- Hammerhead Ribozyme-Based Target Discovery -- Production of siRNA and cDNA-Transfected Cell Arrays on Noncoated Chambered Coverglass for High-Content Screening Microscopy in Living Cells -- Transgenic Animal Models in Biomedical Research -- Keratin Transgenic and Knockout Mice -- The HUVEC/Matrigel Assay -- A Murine Model for Studying Hematopoiesis and Immunity in Heart Failure -- An Overview of the Immune System and Technical Advances in Tumor Antigen Discovery and Validation -- Potential Target Antigens for Immunotherapy Identified by Serological Expression Cloning (SEREX) -- Identification of Tumor Antigens by Using Proteomics -- Protein Arrays.
520			_aTarget discovery is a field that has existed for several years but is so vibrant today because of the recent progress in our understanding of the molecular mechanisms of many human diseases and the technical advances in target identification and validation. More sophisticated gene profiling technologies, such as DNA microarrays and serial analysis of gene expression, permit rapid identification of lead targets. Moreover, analysis of gene networks in living organisms allows the identification of target genes that operate in defined physiological pathways. With the sequencing of several genomes completed and the rapidly growing gene expression databases, there is now greater impetus than ever before for in silico discovery of therapeutic targets. Also, recent advances in genetic technologies have increased our ability to generate mouse models for human diseases. The implications of these genetically modified animals in drug development are several, including identification of new drug targets, predicting efficacy, and uncovering possible side effects. Together, these recent technical advances should allow researchers to make the most informed choice early and advance the chosen targets toward clinical studies. Regarding cancers, any difference between a cancer and a normal cell could potentially be exploited as a therapeutic target. The hope is that drugs targeting specific constituents or pathways in cancer cells will provide more effective therapy, either alone or in combination with other currently used anticancer drugs. In addition to drug targets, identifying new target antigens remains as much of a challenge as improving tumor vaccines already in the clinic.
700	1		_aSioud, Mouldy _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9781617376993
776	0	8	_iPrinted edition: _z9781588296566
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1385/1597451657 _z(usuarios Universidad Europea de Valencia)
942			_2lcc _cLE
988			_aSpringer_Protocols_2007
999			_c234529 _d234529